Foreign Minister S Jaishankar will embark on a five-day visit to the United States next week with the aim of achieving the goal of the acquisition of Covid-19 vaccines and smoothing wrinkles of resources that have severely curtailed the vaccine in India.
The minister is expected to meet with UN Secretary-General Antonio Guterres in New York and hold talks with his counterpart Secretary of State Antony Blinken in Washington DC, India’s foreign ministry said in a statement, adding that he would meet with cabinet members and top UN officials. Biden’s administration dealing with bilateral relations.
He is also expected to have two liaison with business forums on economic and Covid-related cooperation between India and the US, amid frustration on both sides – albeit well-intentioned – on issues such as the supply of raw materials and used psychological materials. put a desire in India to vaccinate its people immediately.
Although Indian ambassador to the United States Taranjit Sandhu held almost daily meetings with pharma majors, including involvement in the last 48 hours with modern-day chief executive Stephane Bance and Johnson & Johnson chairman and CEO Alex Gorsky, there was no legacy. IP issues that could address New Delhi’s urgent need for more than a billion vaccines – more than the modest millions currently being sent.
Breaking free from this problem involving pharma majors seeking to maintain its ownership and profitability requires a high level of government intervention, a requirement that brings the foreign minister to Washington DC during an unusual visit.
The White House said earlier this week that the United States has so far provided more than $ 500 million to Covid in India, including donations from U.S. governments and governments, American companies, corporations and private citizens, but its strong move to release patents have not yet received the full board support in Congress.
In a letter on May 20, more than 100 Republican lawmakers expressed concern over support from Biden’s management for curbing Covid-19 vaccine-related (IP) protection, saying it would serve as a “major supply” to countries such as China, Russia and India.
“It is important that we lead the world in increasing global access to Covid-19 vaccines and ensure our nation’s long history of IP protection to promote efficiency. American jobs, innovation, and global health and well-being are at stake, ”says the letter, fully supporting Big Pharma’s position that it would be better to reduce the availability of vaccines than to offer them in stores.
But lawmakers on the left have repeatedly voiced Big Pharma’s claims for new investments – without any embarrassment at the time – showing that they spend far more on advertising and compensation than R&D.